within Pharmacolibrary.Drugs.ATC.L;

model L01BB05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00015666666666666666,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.015,
    k12             = 16,
    k21             = 16
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BB05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fludarabine is a purine analog used as an antineoplastic agent, primarily for the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphoma. It is approved for clinical use and typically administered intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adult cancer patients after intravenous administration; mixed male and female population with normal renal function.</p><h4>References</h4><ol><li><p>Kuo, GM, et al., &amp; Burstein, AH (2001). Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. <i>Pharmacotherapy</i> 21(5) 528–533. DOI:<a href=&quot;https://doi.org/10.1592/phco.21.6.528.34549&quot;>10.1592/phco.21.6.528.34549</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11349741/&quot;>https://pubmed.ncbi.nlm.nih.gov/11349741</a></p></li><li><p>Kikuchi, T, et al., &amp; Okamoto, S (2021). Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. <i>International journal of hematology</i> 113(1) 128–133. DOI:<a href=&quot;https://doi.org/10.1007/s12185-020-02990-y&quot;>10.1007/s12185-020-02990-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32886279/&quot;>https://pubmed.ncbi.nlm.nih.gov/32886279</a></p></li><li><p>Frampton, JE, &amp; Wagstaff, AJ (2003). Alemtuzumab. <i>Drugs</i> 63(12) 1229–1246. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363120-00003&quot;>10.2165/00003495-200363120-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12790693/&quot;>https://pubmed.ncbi.nlm.nih.gov/12790693</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BB05;
